3 completed, 2 terminated. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 2 |
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow rovalpituzumab tesirine: new trials by email Literature Review of rovalpituzumab tesirine trials Research Report on rovalpituzumab tesirine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Study of Rovalpituzumab Tesirine rovalpituzumab tesirine - Cancer | Phase 2 | Completed | AbbVie | 3 | 2018-09-10 | 2021-01-05 |
| A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer Ipilimumab, Nivolumab, Rovalpituzumab tesirine - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | AbbVie | 42 | 2017-03-30 | 2020-07-17 |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Rovalpituzumab tesirine, Dexamethasone - Malignant Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Terminated | AbbVie | 200 | 2016-09-23 | 2020-10-19 |
| Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Rovalpituzumab tesirine - Small Cell Lung Cancer | Phase 2 | Completed | AbbVie | 342 | 2016-01-25 | 2021-07-30 |
| Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Rovalpituzumab tesirine (SC16LD6.5) - Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Stemcentrx | 82 | 2013-07-01 | 2018-08-09 |
Small Cell Lung Carcinoma (3) · Neoplasms (2) · Carcinoma, Medullary (1) · Glioblastoma (1) · Melanoma (1) · Recurrence (1)
AbbVie (4) · Stemcentrx (1)
United States (4) · France (1) · Germany (1) · Italy (1) · Spain (1)
2015 (1), 2016 (1)